The
global Cancer Biomarkers Market is expected to reach a
value of USD 33.7 billion by 2025, based on a new report by Grand View
Research, Inc. Growing initiatives for development of drugs targeting novel
cancer biomarkers coupled with the introduction of technologically advanced companion
diagnostic kits is estimated to provide the market with high growth potential.
Increasing awareness about personalized medicines amongst patients is further
anticipated to boost adoption of cancer biomarkers.
In
addition, presence of favorable government initiatives for the development of
novel cancer diagnostic techniques is a key factor for market growth. For
instance, the National Cancer Institute (NCI) provides funding to more than 8
research areas pertaining to cancer biomarker development. Cancer Research UK,
Lung Cancer Research Foundation, and National Institutes of Health are some of
the organizations providing funding for biomarker research.
People
with high alcohol consumption, tobacco usage, unhealthy food habits, and
sedentary lifestyle are reported to be 80% more at risk of developing cancer as
compared to other individuals. Infections such as Human papillomavirus (HPV),
Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been
studied to be related in cancer development.
Browse
Details of Report @
http://www.grandviewresearch.com/industry-analysis/cancer-biomarker-market
http://www.grandviewresearch.com/industry-analysis/cancer-biomarker-market
Further Key findings from the study suggest:
- Breast
cancer was the largest segment by revenue share in 2016 owing to high
prevalence of this type of cancer
- Lung cancer
is estimated to be the fastest-growing type due to increasing research
activities toward development of novel lung cancer biomarkers
- Genetic
biomarkers, being the highest used and easily detectable held the majority
share of cancer biomarker market by biomolecule in 2016
- However,
epigenetic biomarkers are anticipated to witness lucrative growth due to
increasing focus on finding the role of epigenetic modifications in cancer
development
- Cancer
biomarkers are majorly used for diagnostic purpose owing to their high
specificity
- The
personalized medicine segment is estimated to witness fastest CAGR of
15.0% over the forecast period
- North
America dominated in terms of revenue share in 2016 due to established
R&D infrastructure and high acceptance of biomarker-based cancer
testing in this region
- Asia Pacific
is anticipated to grow at a substantial growth rate till 2025 with CAGR of
over 16.7%
- Some of the
major companies in the cancer biomarkers market are Abbott Laboratories;
F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.;
Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co.
Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, the company offers market intelligence
studies ensuring relevant and fact-based research across a range of industries
including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment